This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Led by Boyce Thompson Institute’s Andrew Nelson, four partners will identify RNA modifications and develop resources that may lead to hardier crops Credit: Photo credit: Anna Nelson Dittrich ITHACA, NY, August 4, 2020 — RNA perform a variety of functions in cells, helping with everything from regulating genes to building proteins.
Scientists from the iMolecule group at Skoltech Center for Computational and Data-Intensive Science and Engineering (CDISE) developed BiteNet, a machine learning (ML) algorithm that helps find drug binding sites, i.e. potential drug targets, in proteins. BiteNet can analyze 1,000 protein structures in 1.5
Bioinformatics: publication in Nature Communications The most important components for the functioning of a biological cell are its proteins. As a result, protein production is arguably the most important process for cell growth. The faster the bacterial growth rate, the faster protein synthesis needs to take place.
A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. What, then, is the solution? About the interviewee.
“For example, you can simulate what would happen if you inhibited thousands of different proteins in thousands of different cell models.”. They go into bioinformatics”. But with a host of well-educated doctors, biologists, engineers and software developers in the country, this gap has been filled by a strong digital health ecosystem.
CAV1 is a protein associated with poor outcomes in aggressive breast and prostate cancer. Credit: SFU SFU computing science professor Ghassan Hamarneh is using his medical imaging analysis expertise to help UBC researchers understand the role of caveolin-1 (CAV1) in certain cancer types.
AION Labs’ third call for applications seeks computational biologists, bioinformatics and cheminformatics scientists, AI researchers, and antibody or proteinengineers at academic and industry research labs worldwide to assemble a fully funded start-up company.
This impressive growth can be attributed to Fulgent’s distinctive chemistries and advanced proprietary bioinformatics pipeline, which have been instrumental in fueling the company’s rapid advancement in recent years. Alpine Immune Sciences has recently announced an augmentation in its R&D investment. million and $38.8 million and $33.9
Credit: Kanazawa University Nowadays nanotechnology allows to observe single proteins at work. Under atomic force microscopy (AFM), e.g., their surface can be rapidly scanned, and functional motions monitored, which is of great importance for applications in all fields of Life science.
Researchers from Skoltech, Lomonosov Moscow State University, and the Kharkevich Institute for Information Transmission Problems have studied the genomes of some 200 strains of bacteria to determine which proteins in the ribosome, part of the key cell machinery, can be safely lost and why.
“Over the last five years, Teneobio developed leading-edge expertise in efficiently engineering differentiated multispecific and bispecific therapeutics for numerous indications with potentially better safety, efficacy and pharmacokinetic profiles than the first generation of T-cell engagers. chief executive officer of Teneobio.
These vaccines can be engineered to address antigenic variability and stimulate a wide-ranging immune response. These methods often require extensive sample preparation, complex bioinformatics or specialized lab environments, making them less ideal for quality control and release testing, where multiple mRNA constructs are already mixed.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content